In DLD-1 colon cancer reporter cells, sesamin did not significantly suppress basal COX-2 promoter activity at concentrations up to 100 µM after 48 h. This negative result limits generalization of anti-inflammatory activity across cellular assays. [2]
Direct inhibition of recombinant human CYP4F2
Biochemical assay · Commercial recombinant human CYP4F2 microsomes with reductase and cytochrome b5; luciferin-4F2/3 O-dealkylation assay [1]
Sesamin inhibited the reporter-substrate reaction. Kinetics supported mixed-type inhibition; the reported apparent Ki was fitted using a Michaelis–Menten mixed model although substrate kinetics followed a Hill model.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–2.5 µM sesamin with 5 µM luciferin-4F2/3; kinetic series: 0–0.5 µM sesamin and 1–10 µM substrate
- Exposure duration
- 20 min at 37°C
- Method
- Luminescence assay with an NADPH-generating system; zero-sesamin control
- Vehicle
- 0.5% DMSO in all samples
- Reported limits
- No catalog number, lot, analytical stereochemistry or purity reported.
Methods and source locations
Compound reported in the paper: Sesamin; Compound label in the paper: Sesamin
Reporter-substrate biochemical inhibition only; no direct binding, cellular efficacy or clinical blood-pressure claim.
Materials; Inhibition Studies; Statistical Analysis; Results: Inhibition of Human CYP4F2; Figs 1–2 and captions; Table 1
Luciferin-4F2/3 O-dealkylase activity: Nonlinear logistic concentration-response fit; mean ± SD; 3 independent experiments per Fig. 1 caption — Results: Inhibition of Human CYP4F2; Fig. 1/caption; Inhibition Studies
Mixed-type inhibition of luciferin-4F2/3 O-dealkylation: Mixed-type Michaelis–Menten model used as an approximation to Hill kinetics; mean ± SD — Results: Inhibition of Human CYP4F2; Fig. 2; Table 1; Inhibition Studies
Time- and NADPH-dependent CYP4F2 inactivation
Biochemical assay · Same recombinant human CYP4F2 preparation and reporter-substrate system as the direct-inhibition study [1]
Preincubation enhanced inhibition. Time/concentration kinetics and matched NADPH controls supported metabolism-dependent inactivation. The responsible metabolic intermediate was not identified.
Literature-Reported Treatment Conditions
- Treatment concentration
- IC50 shift: 0–2.5 µM sesamin; inactivation kinetics: 0–1 µM; NADPH-dependence comparison: 0.2 µM sesamin
- Exposure duration
- IC50 shift: 0 or 20 min preincubation; kinetic preincubation: 0, 2, 4 or 6 min at 37°C; NADPH control: 6 min
- Method
- Preincubation then reporter activity assay; kinetic aliquots diluted tenfold into assay mixture
- Vehicle
- DMSO; assay method specifies final 0.5% in all samples
- Co-treatment
- NADPH-generating system compared with its omission; no second therapeutic compound
- Reported limits
- No current-lot characterization; chemical identity of the inactivating metabolite remains unknown.
Methods and source locations
Compound reported in the paper: Sesamin; Compound label in the paper: Sesamin
Enzyme inactivation supported by functional controls; molecular intermediate and clinical relevance remain unresolved.
Inactivation Studies; Statistical Analysis; Results: Metabolism-Dependent Inhibition; Figs 3–5/captions; Discussion
Luciferin-4F2/3 O-dealkylase inhibition with versus without preincubation: Corresponding control activities; mean ± SD; 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 3/caption; Inactivation Studies
Time-dependent loss of CYP4F2 activity: Nonlinear fit of observed inactivation rate; mean ± SD; 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 4/caption; Inactivation Studies
Concentration dependence of CYP4F2 inactivation: Half-maximal inactivation concentration; mean ± SD; 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 4/caption; Inactivation Studies
Residual enzyme activity after preincubation: 6-min preincubation; sesamin 0.2 µM; Bonferroni comparison; mean ± SD, 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 5/caption; Inactivation Studies
Limited effect on basal COX-2 promoter activity in DLD-1 cells
Cell-based study · Human DLD-1/COX-2-B2-βGal-BSD reporter cells [2]
Sesamin did not significantly suppress basal COX-2 promoter activity up to 100 µM. Reporter activity was normalized to viable cell number; the authors reported no remarkable suppression of cell proliferation by the tested compounds in the MTT assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 12.5, 25, 50 and 100 µM sesamin
- Exposure duration
- 48 h
- Method
- β-Galactosidase reporter assay with ONPG; normalization by MTT viability assay
- Co-treatment
- Sesamol and other sesame constituents were tested separately, not co-treatments.
- Reported limits
- Treatment solvent is not specified in the retrieved reporter methods. Methods and Fig. 2 caption disagree on seeding density (2 × 10^4 versus 2 × 10^5 cells/well); no density is adopted.
Methods and source locations
Compound reported in the paper: Sesamin; Compound label in the paper: Sesamin
Basal promoter reporter result in one human cancer cell line; no conclusion about stimulated inflammation or sesamin animal antitumor efficacy.
Chemicals; Cell culture; Measurements of cell viability; Reporter gene assay; Statistical analysis; first Results subsection; Fig. 2B/caption
Basal COX-2 promoter reporter activity: β-Galactosidase normalized for MTT viable-cell number at 48 h; triplicate wells, SD; Fig. 2 representative of >3 independent experiments; Bonferroni z test as reported — Abstract; first Results subsection; Fig. 2B/caption; Reporter gene assay and Statistical analysis